Sally Church

albotas: Watch This Girl Build Her Own Prosthetic Leg Out Of LEGO Pieces It’s awesome watching this girl scavenge for all the right pieces (a feeling I’m sure we’re all familiar with), and become increasingly delighted at her progress. See for yourself. The uploader, AmputeeOT, says: Someone in my research lab jokingly suggested I make a... - http://maverickny.tumblr.com/post...

ASH 2012 update on ARRY-520 in multiple myeloma - http://pharmastrategyblog.com/2013...

Will biomarkers revolutionalise treatment with tivozanib? - http://pharmastrategyblog.com/2013...

ASCO GU update on tivozanib in advanced clear cell renal cancer - http://pharmastrategyblog.com/2013...

Tumor Lysis Syndrome – what is it and why is it important in cancer research? - http://pharmastrategyblog.com/2013...

Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal - http://pharmastrategyblog.com/2013...

Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler - http://pharmastrategyblog.com/2013...

Will ASCO GI herald a new era for pancreatic cancer? - http://pharmastrategyblog.com/2013...

Effectively targeting KRAS in lung cancer with a MEK inhibitor - http://pharmastrategyblog.com/2012...

Time to rethink cancer clinical trials strategy? - http://pharmastrategyblog.com/2012...

Zaltrap – a simple dosing error or not? - http://pharmastrategyblog.com/2012...

Update on KRAS in pancreatic cancer - http://pharmastrategyblog.com/2012...

Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012 - http://pharmastrategyblog.com/2012...

Update on bavituximab in non-squamous lung cancer - http://pharmastrategyblog.com/2012...

ASCO 2012 Update 2: Overcoming resistance in metastatic melanoma - http://pharmastrategyblog.com/2012...

A surfeit of riches in CLL and NHL: on bruton kinase and PI3K delta inhibitors - http://pharmastrategyblog.com/2012...

ASCO 2012 Update 1: Advanced Lung Cancer - http://pharmastrategyblog.com/2012...

Interested in the PI3K-AKT-mTOR pathway in cancer research? - http://pharmastrategyblog.com/2012...

Aggregating the 2012 ASCO tweets - http://pharmastrategyblog.com/2012...

Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone - http://pharmastrategyblog.com/2012...

Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases - http://pharmastrategyblog.com/2012...

Reflections of a Medical Oncologist on AACR 2012 - http://pharmastrategyblog.com/2012...

ASCO 2012 Preview – Highlights of key data emerging from Chicago - http://pharmastrategyblog.com/2012...

ASCO 2012 Acronym Mania! - http://pharmastrategyblog.com/2012...

Ribonucleases (RNase) – clinical applications for cancer therapy - http://pharmastrategyblog.com/2012...

Ribonucleases (RNase) what are they and why are they relevant to cancer? - http://pharmastrategyblog.com/2012...

Highlights of AACR 2012 – Part 3 - http://pharmastrategyblog.com/2012...

Highlights of AACR 2012 – Part 2 - http://pharmastrategyblog.com/2012...

Highlights of AACR 2012 – Part 1 - http://pharmastrategyblog.com/2012...

American Society for Cancer Research Meeting 2012 - http://pharmastrategyblog.com/2012...

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer - http://pharmastrategyblog.com/2012...

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR : Nature : Nature Publishing Group - http://www.nature.com/nature...